Logo image of CNTX

CONTEXT THERAPEUTICS INC (CNTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CNTX - US21077P1084 - Common Stock

1.05 USD
+0.02 (+1.94%)
Last: 12/5/2025, 8:11:34 PM
Fundamental Rating

3

CNTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While CNTX has a great health rating, there are worries on its profitability. CNTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CNTX has reported negative net income.
In the past year CNTX has reported a negative cash flow from operations.
CNTX had negative earnings in 4 of the past 5 years.
CNTX had a negative operating cash flow in each of the past 5 years.
CNTX Yearly Net Income VS EBIT VS OCF VS FCFCNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -33.37%, CNTX is in line with its industry, outperforming 49.48% of the companies in the same industry.
CNTX's Return On Equity of -36.13% is in line compared to the rest of the industry. CNTX outperforms 57.81% of its industry peers.
Industry RankSector Rank
ROA -33.37%
ROE -36.13%
ROIC N/A
ROA(3y)-71.84%
ROA(5y)235.37%
ROE(3y)-90.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTX Yearly ROA, ROE, ROICCNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

CNTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTX Yearly Profit, Operating, Gross MarginsCNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for CNTX has been increased compared to 1 year ago.
CNTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNTX Yearly Shares OutstandingCNTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CNTX Yearly Total Debt VS Total AssetsCNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 7.32 indicates that CNTX is not in any danger for bankruptcy at the moment.
CNTX's Altman-Z score of 7.32 is amongst the best of the industry. CNTX outperforms 80.21% of its industry peers.
There is no outstanding debt for CNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.32
ROIC/WACCN/A
WACCN/A
CNTX Yearly LT Debt VS Equity VS FCFCNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

CNTX has a Current Ratio of 13.10. This indicates that CNTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 13.10, CNTX belongs to the top of the industry, outperforming 81.77% of the companies in the same industry.
A Quick Ratio of 13.10 indicates that CNTX has no problem at all paying its short term obligations.
CNTX's Quick ratio of 13.10 is amongst the best of the industry. CNTX outperforms 81.77% of its industry peers.
Industry RankSector Rank
Current Ratio 13.1
Quick Ratio 13.1
CNTX Yearly Current Assets VS Current LiabilitesCNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 69.23% over the past year.
EPS 1Y (TTM)69.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CNTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.34% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y32.83%
EPS Next 2Y9.66%
EPS Next 3Y7.06%
EPS Next 5Y13.34%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTX Yearly Revenue VS EstimatesCNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M 400M
CNTX Yearly EPS VS EstimatesCNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNTX. In the last year negative earnings were reported.
Also next year CNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTX Price Earnings VS Forward Price EarningsCNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTX Per share dataCNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.66%
EPS Next 3Y7.06%

More info and screens

0

5. Dividend

5.1 Amount

CNTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTEXT THERAPEUTICS INC

NASDAQ:CNTX (12/5/2025, 8:11:34 PM)

1.05

+0.02 (+1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-12 2026-03-12/amc
Inst Owners75.25%
Inst Owner ChangeN/A
Ins Owners1.25%
Ins Owner Change0%
Market Cap96.47M
Revenue(TTM)N/A
Net Income(TTM)-26.44M
Analysts84.29
Price Target5.44 (418.1%)
Short Float %0.76%
Short Ratio1.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.1%
Min EPS beat(2)-44.18%
Max EPS beat(2)-4.02%
EPS beat(4)2
Avg EPS beat(4)6.18%
Min EPS beat(4)-44.18%
Max EPS beat(4)57.74%
EPS beat(8)4
Avg EPS beat(8)-0.23%
EPS beat(12)5
Avg EPS beat(12)-12.53%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.22%
PT rev (3m)2.56%
EPS NQ rev (1m)-3.7%
EPS NQ rev (3m)-9.32%
EPS NY rev (1m)-4.57%
EPS NY rev (3m)-7.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.37%
ROE -36.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.84%
ROA(5y)235.37%
ROE(3y)-90.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 225.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.1
Quick Ratio 13.1
Altman-Z 7.32
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)155.66%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y32.83%
EPS Next 2Y9.66%
EPS Next 3Y7.06%
EPS Next 5Y13.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.91%
OCF growth 3YN/A
OCF growth 5YN/A

CONTEXT THERAPEUTICS INC / CNTX FAQ

Can you provide the ChartMill fundamental rating for CONTEXT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to CNTX.


What is the valuation status for CNTX stock?

ChartMill assigns a valuation rating of 0 / 10 to CONTEXT THERAPEUTICS INC (CNTX). This can be considered as Overvalued.


How profitable is CONTEXT THERAPEUTICS INC (CNTX) stock?

CONTEXT THERAPEUTICS INC (CNTX) has a profitability rating of 1 / 10.


What is the financial health of CONTEXT THERAPEUTICS INC (CNTX) stock?

The financial health rating of CONTEXT THERAPEUTICS INC (CNTX) is 8 / 10.